TickerFacts.

Surrozen, Inc. (SRZN): Revenue

Annual figures by period end, from SEC filings.

$3.48M
Year ended 2025-12-31
$11.51M
Trailing 12 months to 2026-06-30
-34.7%
3-year compound annual growth
$12.50M2021-12-31: $02022-12-31: $12.50M2023-12-31: $02024-12-31: $10.65M2025-12-31: $3.48M$3.48M
2021-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$3.48M-67.4%2026-03-23, From 2025-01-01
2024-12-31$10.65Mn/a2026-03-23, From 2024-01-01
2023-12-31$0-100.0%2025-03-31, From 2023-01-01
2022-12-31$12.50Mn/a2024-04-10, From 2022-01-01
2021-12-31$0n/a2023-03-31, From 2021-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Surrozen, Inc. (SRZN)2025-12-31$3.48M-67.4%
CRISPR Therapeutics AG (CRSP)2025-12-31$3.51M-90.6%
Dyadic International Inc (DYAI)2025-12-31$3.09M-11.6%
CG Oncology, Inc. (CGON)2025-12-31$4.04M+254.7%
Ocugen, Inc. (OCGN)2025-12-31$4.41M+8.8%
Prime Medicine, Inc. (PRME)2025-12-31$4.63M+55.3%
Zeo ScientifiX, Inc. (ZEOX)2025-10-31$5.20M+12.5%
Aligos Therapeutics, Inc. (ALGS)2025-12-31$2.19M-39.5%
DBV Technologies S.A. (DBVT)2025-12-31$5.64M+35.8%

Compare SRZN, CRSP, DYAI, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗